NORTHWEST BIOTHERAPEUTICS INC (NWBO)
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Northwest Biotherapeutics, Inc.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) dilution facts from SEC filings
Snapshot as of Sep 30, 2026, built from 13 SEC filings.
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 1 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.